A Double-Blind, Placebo-Controlled Study to Assess the Mitochondria-Targeted Antioxidant MitoQ as a Disease-Modifying Therapy in Parkinson's Disease

被引：444

作者：

Snow, Barry J. ^{[1
]}

Rolfe, Fiona L. ^{[2
]}

Lockhart, Michelle M. ^{[2
]}

Frampton, Christopher M. ^{[3
]}

O'Sullivan, John D. ^{[4
,5
]}

Fung, Victor ^{[6
]}

Smith, Robin A. J. ^{[7
]}

Murphy, Michael P. ^{[8
]}

Taylor, Kenneth M. ^{[2
]}

机构：

[1] Auckland Hosp, Dept Neurol, Auckland, New Zealand

[2] Antipodean Pharmaceut, Auckland, New Zealand

[3] Christchurch Hosp, Dept Med, Christchurch Sch Med & Hlth Sci, Christchurch, New Zealand

[4] Neurol Res Ctr, Div Med, Brisbane, Qld, Australia

[5] Univ Queensland, Sch Clin, Royal Brisbane & Womens Hosp, Brisbane, Qld, Australia

[6] Univ Sydney, Dept Neurol, Westmead Hosp, Sydney Med Sch, Sydney, NSW 2006, Australia

[7] Univ Otago, Dept Chem, Dunedin, New Zealand

[8] MRC, Mitochondrial Biol Unit, Cambridge, England

来源：

MOVEMENT DISORDERS | 2010年 / 25卷 / 11期

关键词：

PD; MitoQ; mitochondria; oxidative damage; neuroprotection; ISCHEMIA-REPERFUSION INJURY; SUBSTANTIA-NIGRA; RATING-SCALE; COENZYME Q(10); TEACHING TAPE; MOTOR SECTION; HUMAN BRAIN; MITOQUINONE; DYSFUNCTION; PROGRESSION;

D O I：

10.1002/mds.23148

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Multiple lines of evidence point to mitochondrial oxidative stress as a potential pathogenic cause for Parkinson's disease (PD). MitoQ is a powerful mitochondrial antioxidant. It is absorbed orally and concentrates within mitochondria where it has been shown to protect against oxidative damage. We enrolled 128 newly diagnosed untreated patients with PD in a double-blind study of two doses of MitoQ compared with placebo to explore the hypothesis that, over 12 months, MitoQ would slow the progression of PD as measured by clinical scores, particularly the Unified Parkinson Disease Rating Scale. We showed no difference between MitoQ and placebo on any measure of PD progression. MitoQ does not slow the progression of PD, and this finding should be taken into account when considering the oxidative stress hypothesis for the pathogenesis of PD. (C) 2010 Movement Disorder Society

引用

页码：1670 / 1674

页数：5

共 30 条

[1] Expanding insights of mitochondrial dysfunction in Parkinson's disease [J].